Description

Product Description

NT 13 (TPPT) is a short-chain peptide composed of the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide, designed to act as a partial agonist of the N-methyl-D-aspartate receptor (NMDAR). Unlike full agonists that may induce excitotoxicity, NT 13 modulates receptor activity in a controlled manner, providing a fine-tuned approach to studying glutamatergic neurotransmission and its impact on mood regulation, learning, and memory.

In the field of neuroscience research, NMDA receptors are well known for their central role in synaptic plasticity, neurodevelopment, and long-term potentiation (LTP), which underlie cognitive processes such as learning and memory formation. Dysregulation of NMDA receptor activity has been strongly associated with neuropsychiatric conditions including depression, schizophrenia, and anxiety disorders. NT 13, as a partial NMDAR agonist, provides researchers with a valuable molecular probe for modulating receptor activity without the risk of overactivation that typically accompanies full agonists.

Studies have shown that NT 13 (TPPT) enhances glutamatergic signaling while maintaining receptor homeostasis, resulting in beneficial effects on synaptic balance and neuronal communication. This unique pharmacological profile makes NT 13 an effective experimental tool for evaluating NMDA receptor dynamics in depression models, as well as for exploring mechanisms of antidepressant response involving glutamate modulation.

Furthermore, NT 13’s short peptide structure allows for better stability and receptor selectivity compared to larger protein-based ligands. Its amide-capped terminus (–NH₂) confers improved resistance to enzymatic degradation, making it suitable for in vitro and in vivo investigations. Researchers often utilize NT 13 to explore the intersection of glutamatergic and monoaminergic systems, examining how NMDA receptor activation can influence serotonin and dopamine pathways involved in emotional regulation.

Because of its balanced agonistic behavior, NT 13 is also being studied for potential roles in neuroprotection and synaptic resilience. Excessive NMDA receptor activation can lead to calcium overload and excitotoxic neuronal death—a major factor in neurodegenerative diseases such as Alzheimer’s and Huntington’s disease. NT 13’s partial agonism limits this excitotoxic cascade while still promoting beneficial receptor-mediated signaling, positioning it as a unique experimental agent in neurodegeneration research.

In summary, NT 13 (TPPT) is a high-purity synthetic tetrapeptide that serves as an invaluable research compound for investigating NMDA receptor pharmacology, depression mechanisms, anxiety pathophysiology, and cognitive modulation. Its biochemical precision, stability, and safety profile make it a preferred reagent for advanced neurobiological studies.

Product Specifications

Mechanism of Action

NT 13 (TPPT) functions as a partial agonist at NMDA receptors, which are ligand-gated ion channels activated by glutamate and glycine. Unlike full agonists such as NMDA or glutamate, NT 13 binds to the receptor’s glutamate-binding site but elicits a submaximal response, effectively regulating calcium ion influx while minimizing excitotoxicity.

This modulated receptor activation maintains calcium-dependent signaling cascades required for neuronal survival and plasticity, including activation of CaMKII, CREB, and BDNF pathways—all of which are implicated in antidepressant efficacy and synaptic strengthening. By avoiding overactivation, NT 13 helps preserve mitochondrial function and neuronal integrity, offering a more physiologically balanced model for studying NMDAR function in stress and depression paradigms.

Furthermore, the peptide’s interaction with the NR1 subunit of the NMDA receptor allows partial channel opening, enhancing neural communication efficiency. This unique pharmacodynamic behavior provides insight into receptor desensitization, downstream signaling regulation, and neurotransmitter balance. NT 13’s modulation of glutamatergic homeostasis has been linked to improved mood stabilization, reduced anxiety, and enhanced cognitive flexibility in experimental systems.

Side Effects

As a laboratory research compound, NT 13 has no reported clinical adverse effects, since it is not intended for human or veterinary use. However, experimental studies highlight that excessive NMDA receptor activation may lead to excitotoxicity, oxidative stress, and mitochondrial dysfunction. Researchers should apply NT 13 at controlled concentrations and follow proper experimental design to avoid overexposure.

When handling NT 13, laboratory safety measures—such as gloves, protective eyewear, and fume hood use—are strongly recommended. The compound is stable under standard laboratory conditions but should be stored properly to prevent hydrolysis or degradation.

Disclaimer

All products are for laboratory research use only. NT 13 (CAS 117928-93-5) is not approved for human or animal consumption. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional safety guidelines.

Keywords

TPPT, NMDA receptor agonist, partial agonist peptide, depression research, anxiety studies, neuropharmacology, synaptic plasticity, NMDA signaling, glutamatergic modulation, cognitive neuroscience, antidepressant mechanisms

Shipping Guarantee

All peptide products are shipped in temperature-controlled, sealed containers to preserve purity and structural integrity. Global express delivery with tracking is available, and products are packaged with desiccant and thermal protection to ensure stability during transit.

Trade Guarantee

We ensure secure international trade, providing transparent documentation (COA, MSDS, HPLC report) and compliance with import/export standards. Payments are processed through verified channels for customer confidence and regulatory assurance.